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ABSTRACT: Introduction: The Human Papilloma Virus (HPV) 
is the most prevalent sexually transmissible disease. The treatment 
of Condyloma Accuminatum is a great challenge because of the 
high recurrence rate and of the lack of any drug efficient in its 
elimination. Objective: To assess the efficacy of the treatment with 
Imuno BCG (Bacillus Calmette-Guérin) for bearers of condylomas 
recurrent for more than 2 years. Patients and Methods: Patients 
with age between 18 and 60 years, having a history of more 
than 2 years of genital warts, were included, attended as from 
01-08-2011; bearers of serious diseases, immunodeficiency or 
users of immune-suppressors, being excluded. The procedure 
adopted began with a biopsy of the wart(s) with local anesthetic, 
followed by the electro-coagulation of all the warts and bases 
of the biopsies, a solution with 80 mg of Imuno BCG dissolved 
in 2 ml of saline solution 0.9% was applied to all the genital 
area, including the cauterized areas. The area was covered with 
plastic for 2 hours and afterwards washed with water. The local 
application of Imuno BCG was repeated for 8 consecutive weeks. 
At the end of the second month the cases were re-assessed. When 
there was clinical recurrence a new procedure with the same drug 
was undertaken, but with 3 weekly applications made by the 
patient himself for 8 weeks. Result: Sixteen patients completed 
2-year follow-up. The cure rate was of 62.5%. Of the 10 patients 
cured, 6 (37.5%) used one series of Imuno BCG, 1 (6.25%) used 
2 series, and 3 (18.75%) used 3 series. Of the 6 patients who were 
not cured, there was a reduction in the number of cauterizations 
from 5.5 times (over an average period of the disease of 51.6 
months) to 2.4 cauterizations (over an average follow-up period 
of 52.3 months) after the use Imuno BCG. The collateral effects 
of the use of Imuno BCG were insignificant. Conclusion: Topical 
BCG is a good option for the treatment of recurrent condylomas, 
with minimal collateral effect. It may be used even on PPD-
negative patients. However, this result must be confirmed with 
larger sample populations and control-group studies.
Keywords: Condylomata acuminata; Papillomaviridae; 
Mycobacterium bovis.
RESUMO: Introdução: O Papiloma Virus Humano é a doença 
sexualmente transmissível de maior prevalência. O tratamento do 
Condiloma Acuminado é um grande desafio devido ao elevado 
índice de recidiva (30-70%) e à inexistência de medicamento 
eficaz para sua eliminação. Objetivo: Avaliar a eficácia do 
tratamento com OncoBCG  para portadores de condilomas 
recidivantes por mais de 2 anos. Pacientes e métodos: Foram 
incluídos pacientes entre 18 e 60 anos, com história de verrugas 
genitais há mais de 2 anos, atendidos a partir de 01-08-2011, sendo 
excluídos os portadores de doenças graves,  imunodeficiência ou 
em uso de imunossupressor. O método foi: iniciar com biopsia(s) 
da verruga(s) com anestesia local, seguida de eletrocoagulação 
de todas as verrugas e bases das biopsias, e aplicação de solução 
com 80 mg de Onco BCG dissolvido em 2 ml de solução salina 
a 0,9%, em toda área genital, inclusive nas áreas cauterizadas. 
Cobrir a área com plástico por 2 horas, e, depois lavar com 
água. As aplicações locais de Onco BCG foram repetidas por 8 
semanas consecutivas. No final do segundo mês os casos foram 
reavaliados. Quando havia recidiva clínica um novo procedimento 
com o mesmo medicamento era feito, porém com 3 aplicações 
semanais pelo próprio paciente por 8 semanas. Resultado: 
Dezesseis pacientes completaram seguimento de 2 anos. O índice 
de cura foi de 68,75%. Dos 11 pacientes curados, 6 (37,5%) 
usaram uma série de Onco BCG, dois usaram 2 (12,5%) séries, e 
3 (18,75%)  usaram 3 séries. Dos 5 pacientes  não curados, houve 
redução de número de cauterizações de 5,5 vezes num período 
médio de doença de 51,6 meses, para 2,4 vezes de cauterizações, 
num período médio de acompanhamento de 52,3 meses, após 
uso de Onco BCG. Os efeitos colaterais com o uso do BCG são 
insignificantes. Conclusão: BCG tópico é boa opção no tratamento 
para condilomas resistentes, com mínimo efeito colateral e pode 
ser usado mesmo nos pacientes PPD negativos. No entanto, esse 
resultado deve ser confirmado com maior casuística e estudo 
com grupo controle. 
Descritores: Condiloma acuminado; Papillomaviridae; 
Mycobacterium bovis.
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INTRODUCTION
Anogenital Human Papilloma Virus (HPV) is the most frequent sexually transmitted disease 
(STD) at the present time, with a prevalence of 30 to 50% 
in the female university students of the United States1. It 
is calculated that 75-80% of the sexually active population 
will be affected by HPV at some time during their lives2. 
It is important to point out that the use of preservatives 
diminishes the rate of contamination but does not hinder 
the infection3
The basic treatment consists of the destruction of 
condylomatous lesions by mechanical, physical or chemical 
means. All the forms of treatment, when well prescribed and 
adequately applied produce good results and have similar 
efficacy4. The rates of recurrence vary from 30-70%5-7, and 
have significant psychological impact on both the patient 
and their family members. With a view to reducing the 
recurrence rate, many agents have been used as stimulators 
of local immunity6,8.
The Imuno BCG (Bacillus Calmette-Guérin) used 
to reduce the recurrence of vesical tumors is constituted of 
inactivated Bovine Mycobacterium and acts as a stimulator 
of local cytotoxic immunity. It was used as a topical 
genital cream on bearers of HPV and shows a reduction 
in the recurrence of condylomas, with minimal collateral 
effects9,10.
Our objective was to undertake a prospective study 
to assess the index of condyloma recurrence after treatment 
with Imuno BCG in patients who were bearers of HPV 
whether treated or not with other medicines, for at least 
two years.
Patients and methods
Included in the study were masculine patients of 
between 18 and 60 years of age, with a history of genital 
warts of over two years and with the signed declaration of 
informed consent, attended in the Outpatients Department 
of the STD of the Urology Division of the Hospital das 
Clínicas, of the Medical School of the University of São 
Paulo (HC-FMUSP), as from 01-08-2011. Only those who 
had been treated and had been followed up for at least two 
years were included in the analysis. Bearers of serious 
diseases, who were immune-deficient or who were using 
an immune-suppressor were excluded. This study received 
the approval of the Ethics Commission of the HC-FMUSP.
Hemogram, glycemia, creatinin, sorology for 
hepatites B and C, HIV, syphilis, initial urine jet for urinary 
sediment, radiography of the thorax from the front position 
and right side and PPD were collected. The visual physical 
exam was made with the help of a magnifying glass with 
magnification of 3 and 6 times to identify papules and warts. 
Under local anesthetic with lidocaine 2% at the base of the 
places affected. One proceeded to the biopsy of the papules 
and/or warts followed by the electro-cauterization of the 
papules, warts and bases of the biopsies. The products of 
the biopsies were sent for pathological anatomy.
Immediately after the cauterizations 80 mg of Imuno 
BCG dissolved in 2 ml of saline solution at 0.9% was 
applied throughout the genital area, the supra-pubic region 
and the crural regions, including the cauterized areas. The 
area applied was covered with plastic of the “Magipac” 
type for 2 hours, followed by washing with water. The local 
applications of Imuno BCG were repeated once a week for 
8 consecutive weeks, undertaken by the nursing staff in 
the Urology Outpatients Department of the HC-FMUSP.
The patients were re-examined at the end of 
the second month for an assessment of the results and 
the collateral effects. The cases who presented clinical 
recurrence were submitted to a new procedure and were 
treated again, with the same medicine, though with 
applications 3x per week for 8 weeks, made by the patients 
themselves at home. The patients who presented a new 
clinical recurrence were submitted to the new procedure 
and were treated again, with the same medicine but with 
applications 3x per week for 12 weeks.
The following were assessed: a) Rate of cure; b) 
complications: pain, local hyperemia, local and systemic 
wounds and infections.
RESULT
Sixteen patients fulfilled the requirements and were 
included in the study. The average age of the patients was 32 
(21-46) years, with a first sexual relationship at 15.3 (11-19) 
years of age. Each patient had intercourse, on average, with 
more than 21 persons (3-80) before the time of their first 
consultation at our service. Nine of these patients had new 
partners after the treatment with BCG. Before this study, 
three patients had never been treated and 13 of them had 
been treated with cauterizations and had used 5-fluorouracil 
or imiquimod or podophyllotoxin or podophyllin or acid. 
Two patients with a prepucial ring and condyloma in the 
prepuce were submitted to postectomy.
The patients who went for 2 years without exophytic 
lesions were considered cured. Of the 16 patients treated, 
10 (62.50%) were free of exophytic lesions. Of the 10 
patients were free of exophytic lesions, 6 (37.5%) used only 
one course of Imuno BCG, one (6.25%) used two series 
of BCG, and 3 (18.75%) used 3 series of BCG. Of the 8 
patients who used a second series of Imuno BCG, 1 became 
free of exophytic lesions. Of the 4 patients who used a third 
series of Imuno BCG, 3 became free of exophytic lesions. 
Of the 6 patients who were free of exophytic lesions with 
one series of Imuno BCG, 2 were submitted to a simple 
cauterization. The patient who was cured with two series of 
Imuno BCG, was also submitted to a simple cauterization.
As regards the 6 (37.5%) patients who were not 
cured, there was a reduction in the number of cauterizations 
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from 5.5 times (without counting the use of podophyllin 
for 2 years and the use of acid on two other patients for 
the purpose of “cauterizing” the wart), with an average 
duration of the disease from 51.6 (24-96) months, to 2.4 
cauterizations during an average period of follow-up of 
52.3 (28-65) months after the use of Imuno BCG. One of 
these patients was classified as “not cured”, but has been 
17 months without exophytic lesions.
All the patients had normal blood tests and simple 
radiography of the thorax. Of the PPD tests before the 
procedures with Imuno BCG: ten had no reaction to PPD (0 
mm), 5 had respective reactions of 8 mm, 10 mm, 12 mm, 
17mm, 20 mm, and 1 patient did not return for the reading. 
The patients who had reactions to the PPD 10 mm or greater 
were recommended for assessment by an Infectologist, but 
no evidence of infection by tuberculosis was found in any 
of them. After the procedure with Imuno BCG, of the 10 
with PPD zero mm, five remained with PPD 0 mm, one 
with 4 mm, two with 5 mm, one with 18 mmand one did 
not do PPD after Imuno BCG.
Of the patients with PPD zero prior to the Imuno 
BCG, 4 were submitted to the application of Imuno BCG 
with multiple punctures with an insulin needle in the area 
applied, mainly around the site of the cauterized warts. 
Of these 4 patients, one continued to have PPD test zero, 
one of 4 mm, one of 17 mm and one of 18 mm. Of these 4 
patients, 2 were free of exophytic lesions. All of the patients 
had granulomas, which regressed spontaneously without 
bothering the patient. In the patient who had the PPD of 18 
mm, 2 proceedings with Imuno BCG with puncture were 
performed, and after the second puncture, granulomas of 
up to 1 cm were formed. Fifteen months later, excision of 
the granuloma of 6 mm on the prepuce was undertaken as 
was cauterization of the warts. The anatomical-pathological 
(AP) exam of the granuloma showed granuloma with 
caseous necrosis with BAAR (acid-alcohol resistant 
bacillus) research and immune-histochemistry for Koch 
Bacillus negative. The AP examination of the warts was 
Squamous Papilloma.
Six patients with PPD test of 0 mm received BCG 
without puncture and five of them were cured. Of those 
cured who had PPD 0 mm, 3 continued to have PPD 0 
mm and 2 had a reaction of 5 mm to the PPD. No patient 
presented local irritation, systemic reaction or fever, except 
for the formation of granuloma in those patients in whom 
a puncture had been made.
DISCUSSION
The treatment of recurrent acuminated condylomas 
continues to be a challenge for medicine. Ho11 reports that 
91% of persons eliminate HPV infection in up to 2 years. 
Ten percent of people do not succeed in eliminating the 
virus and about 1% of patients present recurrent genital 
warts. For the purpose of reducing the rate of recurrence 
Bohler12 in 1995 used BCG cream for the first time, 
achieving remission in 4 of his 6 patients, though they were 
patients with duration of the disease of less than 18months, 
and only one patient had had the disease for more than 2 
years. We included in this present study only patients with 
a history of condyloma of more than two years precisely 
to reduce the influence of the development of the natural 
immunity of the body in the face of infection by HPV11,13, 
in the rate of cure.
Metawea et al.9 and Salem et al.14 only applied BCG 
in patients with PPD (+). In our study we applied BCG in 
both PPD (+) and (-) patients, and no patient had fever or 
any sign of local or systemic infection. Reaction to PPD 
does not indicate that there will be a better result in the 
elimination of the warts.
BCG cream was only applied on the warts9,10 or only 
to the already healed cauterized area12. We applied it across 
the whole genital, supra-pubic and crural area, whether 
cauterized or not, because we believe that it permits a better 
coverage of the medicine in those areas which are potential 
wart-forming ones.
Bohler12, in the treatment of recurrent condylomas 
of characteristics closer to those of our patients, followed 
them up for more than two years in 2 cases, and followed 
up for up to 12 months the remaining 3 cases. Under these 
conditions he obtained an 83 % cure rate. Using BCG on 
patients who had never been treated before, Bohler et al.10 
obtained a cure rate of 60%, and Metawea et al.9 had a cure 
rate of 80%, in both cases with follow-up of less than 1 year.
We counted as cured only those patients who were 
not recurrent after 2 years of follow-up since the last 
cauterization, because we had 3 patients who were recurrent 
at about 20 months. Our cure rate was of 62.5%, slightly 
inferior to Bohler’s12 in cases of recurrent condylomas; 
however, our inclusion criteria in terms of duration of 
disease and follow-up time are greater. In the 6 (37.5%) 
patients calculated as uncured, one has already gone for 17 
months without warts. Two patients relapsed at close to 2 
years, though they did not return for treatment.
Grupta15 injected BCG directly into the lesions 
and succeeded in eliminating the wart in the two patients 
treated; however, our cases in which puncturing was used 
did not have a better result than those whose application 
was made only on the skin. Can it be that injection into the 
lesion, obtaining an effectively greater dose, has greater 
immunological effect? 
Imiquimod cream 5%, recommended by the CDC16, 
presents a wart elimination rate of 37 to 52%, with a 
recurrence rate of 13% at 3 months and 23% at six months’ 
follow-up17. We believe that with a longer follow-up time, 
this recurrence rate would be comparable to ours (31.25%). 
Kumar et al.18 compared intralesional BCG with imiquimod 
cream 5% and showed slight superior resolution in the BCG 
group, 67/59% (p = 0.52).
Bohler et al.12 reported 1 case (16%) of fever 
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and edema of the penis which hindered the continuation 
of treatment. In another study10 he had 2 cases (20%) of 
fever of 38 and 40 degrees on the first day. Metawea et 
al.9 reported 5 (25%) cases of hyperemia with a passing 
sensation of burning. None of our patients complained of 
fever or hyperemia or local irritation, even in those cases 
in which puncturing had been used.
CONCLUSION
Topical BCG is a good treatment option for resistant 
condylomas, with minimal collateral effect. It can be 
applied evenin patients who do not react to the PPD test. 
However, to obtain more affirmative conclusions greater 
sample populations and group control study are necessary.
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